Clinical characteristics and treatment patterns of patients with hyperkalaemia prescribed sodium zirconiumcyclosilicate (SZC) in a large UK hospital setting: an observational study

Hyperkalaemia, or high levels of potassium in the blood, can lead to serious health issues, particularly for those with kidney problems or metabolic disorders like diabetes. Sodium Zirconium Cyclosilicate also known as Lokelma, is a newly approved treatment for hyperkalaemia that helps the body eliminate excess potassium. Despite its approval and routine use in practice, there is a need to understand how it is being utilised in real-life clinical settings. This study aims to provide insights into the treatment and management of hyperkalaemia using Lokelma within a large hospital setting. The objectives are to describe baseline characteristics of patients receiving Lokelma for the first time, analyse healthcare resource use of Lokelma-treated patients, and treatment patterns during hospitalization and at discharge. This will involve a thorough analysis of anonymised patient records from the hospital database, providing crucial information about the real-world use of Lokelma and how it impacts patient care. Understanding these aspects will offer valuable guidance to healthcare practitioners, allowing them to tailor Lokelma treatment effectively for their patients' needs and optimise healthcare resources efficiently during the management of hyperkalaemia.